Lung Cancer Therapeutics – Driven by Next Generation Drugs

London 11/24/2012 10:01 PM GMT (TransWorldNews)

Global demand for non-small cell lung cancer therapeutics is predicted to achieve levels of $13.3 billion by 2015 driven by increasing numbers of lung cancer cases, greater understanding of non-small cell lung tumours, and the advancement of new therapies focussed on growth factor pathways.

Lung cancer is one of the most common types of cancers across the world, which not only increases mortality rates but also enhances the financial burden on the society. The global market for lung cancer therapeutics is driven by factors such as line extensions for existing products, introduction of innovative products, and advancements in biotechnology. Cytotoxics such as cisplatin, carboplatin, docetaxel (Taxotere), paclitaxel and gemcitabine (Gemzar) continue to dominate the lung cancer pharmaceuticals market, although targeted therapies have begun to create an impact on the market. The lack of data proving the clinical efficacy of targeted drugs contributes to the continued use of cytotoxics for lung cancer treatment.

According to Global Industry Analysts, Tarceva is expected to continue its dominance in the global market for lung cancer therapeutics, while the approvals of Avastin, Erbitux, Zactima, as well as other novel therapies are expected to offer enhanced growth opportunities. Though the patents of three major chemotherapy drugs - Paraplatin (carboplatin), Taxotere (docetaxel) and Gemzar (gemcitabine) are set to expire before 2012, the emergence of new drugs/therapies is expected to offset the revenue decline.

The United States and Europe collectively dominate the global non-small cell lung cancer therapeutics market. The market for non-small cell lung cancer therapeutics in the United States is driven by the introduction of new immunotherapies and increased uptake of VEGF (vascular endothelial growth factor) inhibitors such as Avastin. In addition, the introduction of targeted drugs such as Erbitux and Zactima is expected to boost sales of non-small cell lung cancer therapy market. The introduction of Pfizer's ProMune for advance stage NSCLC and Merck Serono's Stimuvax for stage III NSCLC is expected to boost growth prospects in the near term.

Leading players in the global lung cancer therapeutics market include AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly & Co., F. Hoffmann-La Roche Ltd, Genentech Inc., GlaxoSmithKline Plc, Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals Inc., and Sanofi-Aventis, among others.

The report titled Lung Cancer Therapeutics: A Global Strategic Business Report by Global Industry Analysts, provides a review of market trends, product introductions/innovations, and recent industry activity. The report analyzes market data and analytics for Non-Small Cell Lung Cancer Therapeutics across the following regions - United States, Europe, and Rest of World. Global Industry Analysts©.

 



Click for Report details:Lung Cancer Therapeutics: A Global Strategic Business Report



enquiries@companiesandmarkets.com
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market-Research/Lung-Cancer-Therapeutics-A-Global-Strategic-Business-Report/RPT743510?aCode=e7702a5b-ad88-47dd-bb7a-a58072d4bda2

 

News Alerts

Receive alerts for Companiesandmarkets.com to your inbox. Sign up for News Alerts